Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity

Alexandros Ardavanis, Stella Koumna, Ioannis Fragos, Savvoula Malliou, Flora Kyriakou, Ioannis Mantzaris, Andreas Scorilas, Gerassimos Rigatos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

Original languageEnglish (US)
Pages (from-to)2409-2415
Number of pages7
JournalAnticancer Research
Volume28
Issue number4 C
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Survival
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Erlotinib Hydrochloride
Survival Rate
Retrospective Studies
Therapeutics
Research

Keywords

  • Advanced non-small cell lung cancer
  • Erlotinib
  • Monotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ardavanis, A., Koumna, S., Fragos, I., Malliou, S., Kyriakou, F., Mantzaris, I., ... Rigatos, G. (2008). Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity. Anticancer Research, 28(4 C), 2409-2415.

Erlotinib monotherapy in patients with advanced non-small cell lung cancer : An effective approach with low toxicity. / Ardavanis, Alexandros; Koumna, Stella; Fragos, Ioannis; Malliou, Savvoula; Kyriakou, Flora; Mantzaris, Ioannis; Scorilas, Andreas; Rigatos, Gerassimos.

In: Anticancer Research, Vol. 28, No. 4 C, 07.2008, p. 2409-2415.

Research output: Contribution to journalArticle

Ardavanis, A, Koumna, S, Fragos, I, Malliou, S, Kyriakou, F, Mantzaris, I, Scorilas, A & Rigatos, G 2008, 'Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity', Anticancer Research, vol. 28, no. 4 C, pp. 2409-2415.
Ardavanis, Alexandros ; Koumna, Stella ; Fragos, Ioannis ; Malliou, Savvoula ; Kyriakou, Flora ; Mantzaris, Ioannis ; Scorilas, Andreas ; Rigatos, Gerassimos. / Erlotinib monotherapy in patients with advanced non-small cell lung cancer : An effective approach with low toxicity. In: Anticancer Research. 2008 ; Vol. 28, No. 4 C. pp. 2409-2415.
@article{ce7824e9c8364f539a8a1551b0c839dc,
title = "Erlotinib monotherapy in patients with advanced non-small cell lung cancer: An effective approach with low toxicity",
abstract = "Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81{\%}) male, 7 (19{\%}) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7{\%}, while the disease control rate was 81{\%}. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.",
keywords = "Advanced non-small cell lung cancer, Erlotinib, Monotherapy",
author = "Alexandros Ardavanis and Stella Koumna and Ioannis Fragos and Savvoula Malliou and Flora Kyriakou and Ioannis Mantzaris and Andreas Scorilas and Gerassimos Rigatos",
year = "2008",
month = "7",
language = "English (US)",
volume = "28",
pages = "2409--2415",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 C",

}

TY - JOUR

T1 - Erlotinib monotherapy in patients with advanced non-small cell lung cancer

T2 - An effective approach with low toxicity

AU - Ardavanis, Alexandros

AU - Koumna, Stella

AU - Fragos, Ioannis

AU - Malliou, Savvoula

AU - Kyriakou, Flora

AU - Mantzaris, Ioannis

AU - Scorilas, Andreas

AU - Rigatos, Gerassimos

PY - 2008/7

Y1 - 2008/7

N2 - Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

AB - Background: Treatment of non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) and particularly erlotinib (Tarceva) has been a field of intense research. This retrospective study was conducted to assess the efficacy of erlotinib and its impact on survival. Patients and Methods: Patients with stage IIIB or IV, advanced or recurrent metastatic NSCLC were included in the study and were administered erlotinib 150 mg daily, at different lines of treatment. Results: Thirty-six patients were included in the study: 29 (81%) male, 7 (19%) female. At the time of analysis, all patients had progressed and died. Median progression-free survival (PFS) was 4 months ± 2.43 months (range 0-8 months), whereas median overall survival (OS) was 7 months ± 2.65 months (range 3-15 months). Patients with ECOG performance status of 0 or 1 had better OS and significantly higher PFS rates. Overall response rate was 16.7%, while the disease control rate was 81%. Conclusion: Erlotinib is effective and well tolerated in pretreated patients with advanced NSCLC and a good performance status.

KW - Advanced non-small cell lung cancer

KW - Erlotinib

KW - Monotherapy

UR - http://www.scopus.com/inward/record.url?scp=48849110458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849110458&partnerID=8YFLogxK

M3 - Article

C2 - 18751427

AN - SCOPUS:48849110458

VL - 28

SP - 2409

EP - 2415

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 C

ER -